These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31781628)

  • 41. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer.
    Ross JS; Wang K; Elkadi OR; Tarasen A; Foulke L; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Chmielecki J; Ali SM; Elvin J; Morosini D; Miller VA; Stephens PJ
    J Clin Pathol; 2014 Sep; 67(9):772-6. PubMed ID: 24978188
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma.
    Zhou Z; Zhu L; Niu X; Shen S; Zhao Y; Zhang J; Ye J; Han-Zhang H; Liu J; Liu C; Lu S
    Thorac Cancer; 2019 Apr; 10(4):839-847. PubMed ID: 30793508
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genomic based analyses reveal unique mutational profiling and identify prognostic biomarker for overall survival in Chinese small-cell lung cancer.
    Wang Y; Han X; Wang X; Sheng W; Chen Z; Shu W; Han J; Zhao S; Dai Y; Wang K; Shi W; Yang Z
    Jpn J Clin Oncol; 2019 Dec; 49(12):1143-1150. PubMed ID: 31612912
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.
    Rudin CM; Durinck S; Stawiski EW; Poirier JT; Modrusan Z; Shames DS; Bergbower EA; Guan Y; Shin J; Guillory J; Rivers CS; Foo CK; Bhatt D; Stinson J; Gnad F; Haverty PM; Gentleman R; Chaudhuri S; Janakiraman V; Jaiswal BS; Parikh C; Yuan W; Zhang Z; Koeppen H; Wu TD; Stern HM; Yauch RL; Huffman KE; Paskulin DD; Illei PB; Varella-Garcia M; Gazdar AF; de Sauvage FJ; Bourgon R; Minna JD; Brock MV; Seshagiri S
    Nat Genet; 2012 Oct; 44(10):1111-6. PubMed ID: 22941189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeted next-generation sequencing for cancer-associated gene mutation and copy number detection in 206 patients with non-small-cell lung cancer.
    Zheng S; Wang X; Fu Y; Li B; Xu J; Wang H; Huang Z; Xu H; Qiu Y; Shi Y; Li K
    Bioengineered; 2021 Dec; 12(1):791-802. PubMed ID: 33629637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population.
    Huang Q; Zhou Y; Wang B; Zhao Y; Zhang F; Ding B
    BMC Med Genomics; 2022 Jul; 15(1):146. PubMed ID: 35778737
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
    Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
    Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The genetic landscape of 87 ovarian germ cell tumors.
    Van Nieuwenhuysen E; Busschaert P; Neven P; Han SN; Moerman P; Liontos M; Papaspirou M; Kupryjanczyk J; Hogdall C; Hogdall E; Oaknin A; Garcia A; Mahner S; Trillsch F; Cibula D; Heitz F; Concin N; Speiser P; Salvesen H; Sehouli J; Lambrechts D; Vergote I
    Gynecol Oncol; 2018 Oct; 151(1):61-68. PubMed ID: 30170975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers: Results From a Retrospective Multicenter Cohort Study.
    Thomas A; Mian I; Tlemsani C; Pongor L; Takahashi N; Maignan K; Snider J; Li G; Frampton G; Ali S; Kim S; Nichols S; Rajapakse V; Guha U; Sharon E; Fujimoto J; Moran CA; Wistuba II; Wei JS; Khan J; Szabo E; Torres AZ; Carson KR
    Chest; 2020 Oct; 158(4):1723-1733. PubMed ID: 32464188
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.
    Martin D; Abba MC; Molinolo AA; Vitale-Cross L; Wang Z; Zaida M; Delic NC; Samuels Y; Lyons JG; Gutkind JS
    Oncotarget; 2014 Oct; 5(19):8906-23. PubMed ID: 25275298
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
    Millis SZ; Jardim DL; Albacker L; Ross JS; Miller VA; Ali SM; Kurzrock R
    Cancer; 2019 Apr; 125(7):1185-1199. PubMed ID: 30582752
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship of PI3K-Akt/mTOR/AMPK signaling pathway genetic mutation with efficacy and prognosis in nasopharyngeal carcinoma.
    Chen Y; He Q; Ma H; Zhang L; Liu F; Han Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):165-173. PubMed ID: 35545406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.
    Paik PK; Shen R; Won H; Rekhtman N; Wang L; Sima CS; Arora A; Seshan V; Ladanyi M; Berger MF; Kris MG
    Cancer Discov; 2015 Jun; 5(6):610-21. PubMed ID: 25929848
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors.
    Asiedu MK; Thomas CF; Dong J; Schulte SC; Khadka P; Sun Z; Kosari F; Jen J; Molina J; Vasmatzis G; Kuang R; Aubry MC; Yang P; Wigle DA
    Clin Cancer Res; 2018 Apr; 24(7):1691-1704. PubMed ID: 29351916
    [No Abstract]   [Full Text] [Related]  

  • 57. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transformation from EGFR/PTEN co-mutated lung adenocarcinoma to small cell carcinoma in lymph node metastasis.
    Hayashi T; Takamochi K; Kohsaka S; Kishikawa S; Suehara Y; Takahashi F; Suzuki K; Saito T; Yao T
    Pathol Int; 2020 May; 70(5):295-299. PubMed ID: 32162763
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.
    He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B
    Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Significantly mutated genes and regulatory pathways in SCLC-a meta-analysis.
    Sundaresan V; Lin VT; Liang F; Kaye FJ; Kawabata-Iwakawa R; Shiraishi K; Kohno T; Yokota J; Zhou L
    Cancer Genet; 2017 Oct; 216-217():20-28. PubMed ID: 29025592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.